Comparative Pharmacology
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER versus LOPRESSOR.
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist with rapid onset and short duration of action; reduces heart rate, myocardial contractility, and blood pressure; no intrinsic sympathomimetic activity or membrane stabilizing activity.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
Intravenous loading dose: 500 mcg/kg over 1 minute, followed by maintenance infusion: 50 mcg/kg/min for 4 minutes; if adequate response not achieved, repeat loading dose and increase maintenance infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 6–12 min) in healthy adults; prolonged to 15–20 min in hepatic impairment. Clinical context: rapid offset allows precise titration.
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Rapid hydrolysis by esterases in blood and tissues to inactive acid metabolite (ASL-8123) and methanol. Less than 2% excreted unchanged in urine. Renal elimination of metabolite accounts for >80% of dose; <5% fecal.
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category A/B
Category C
Beta-Blocker
Beta-Blocker